Islamic Finance Principles Assessment
Riba — Does Aubrai by Bio involve interest?
Aubrai's design does not rely on interest-bearing debt instruments or fixed-return lending as its core mechanism. Revenue is generated through trading and market-making fees redirected to research funding, and staking rewards are variable rather than fixed. For Muslim investors, the absence of explicit riba structures is a positive, though the variable, fee-driven nature of returns still warrants scrutiny of underlying speculative volume.
Assessment: Moderate Riba
Score: 64.5/100
Our methodology examines 10 criteria to evaluate how well Aubrai by Bio avoids interest-based mechanisms.
Aubrai's stated revenue comes from a 1% secondary-market trading fee, split 70% to the project treasury and 30% to the protocol, reportedly accumulating from roughly $100K to over $275K, directed toward funded studies like the RMR2 mouse-rejuvenation research. This is fee income tied to market activity rather than interest on loans or bonds. The treasury sits in a DAO-controlled multi-sig for community incentives and research funding. No sources indicate these treasury funds are placed in interest-bearing instruments, and no lending/borrowing function exists natively within the AUBRAI protocol itself, which is a favorable structural feature.
AUBRAI holders can stake tokens to earn "BioXP" points, granting participation rights in future BioAgent Ignition Sales rather than a fixed monetary yield; roughly 20% of Ignition Sale tokens are reported staked. BioXP points reportedly expire 14 days after being earned, reinforcing that this is a participation-access mechanism rather than an interest-bearing deposit. A parallel BIO staking system operates similarly. Because rewards are non-fixed, access-based, and untied to guaranteed principal return, this structure does not resemble riba in the conventional sense, though the lack of detailed lock-up, custody, or slashing terms leaves some mechanics unclear.
Gharar — How much uncertainty does Aubrai by Bio involve?
Aubrai carries a moderate degree of uncertainty stemming from documentation gaps rather than outright anonymity or fraud. Named figures like Dr. Aubrey de Grey and Paul Kohlhaas lend credibility, while missing audits and unclear staking mechanics increase informational risk. On balance, the project is more transparent than a typical meme coin, but investors should treat unresolved technical disclosures as a real gharar concern.
Assessment: Excessive Gharar (High Uncertainty)
Score: 48.9/100
Our methodology examines 15 criteria including team transparency, audit quality, and governance.
Aubrai is publicly associated with named, credentialed figures: longevity researcher Dr. Aubrey de Grey and Bio Protocol founder Paul Kohlhaas, both quoted and identified across multiple outlets. This is a meaningful contrast to anonymous meme projects. However, one source notes the broader "Bio" development team maintains some anonymity, emphasizing product milestones over personal identity. The BioAgent framework has been open-sourced, which supports technical transparency. Overall, disclosure quality is above average for the category, though not complete, since core development personnel behind day-to-day execution remain only partially named.
No security audit specific to AUBRAI or its smart contracts appears in available records; audit reports found in the broader corpus (Halborn's work for SSP Wallet and Ondo Finance) belong to unrelated projects and cannot be extended to Aubrai. This absence of a project-specific audit is a genuine gharar concern that should be stated plainly, since smart-contract risk remains unverified by an independent third party. Legal documentation does classify AUBRAI as a "Utility Token (DAO Governance)" with defined voting rights, and vesting schedules are disclosed, which partially offsets the uncertainty, but the missing audit remains an open risk.
Maysir — Does Aubrai by Bio involve gambling or speculation?
Aubrai is not designed as a pure gambling instrument, but its secondary market has displayed intense speculative behavior. What distinguishes it from a maysir-first project is the underlying research function and revenue-generating fee structure. Still, price action detached from that utility raises legitimate concern for cautious investors.
Assessment: Moderate Maysir (High Risk)
Score: 50/100
Our methodology examines 11 criteria to determine whether Aubrai by Bio is a gambling instrument or a genuine economic tool.
While Aubrai brands itself as DeSci infrastructure rather than a meme coin, its token has experienced extreme, casino-like price swings, reportedly rising roughly 150x from presale FDV before later retracing. Such volatility, driven largely by speculative trading rather than the pace of underlying scientific output, mirrors the dynamics of maysir where gains depend on price momentum rather than productive economic activity. This does not mean the project's core function is gambling, but it does mean that a large share of current market behavior around the token is speculative rather than utility-driven.
Weighed against this, Aubrai does channel real fee revenue toward funded longevity research (e.g., the RMR2 study) and produces tangible outputs like IP-NFTs and open-sourced AI frameworks, which represent genuine, non-speculative utility largely absent in typical meme coins. The Ignition Sale being oversubscribed 13.5x and restricted to existing BIO/BioXP holders suggests some structured, utility-linked demand rather than pure open speculation. Nonetheless, the scale of secondary-market price movement far outpaces the scale of research funding generated, meaning speculative trading currently dominates the token's observable market activity.
The Full 27-Point Screening
1. Legitimacy (4 criteria)
| Criterion | Score | Analysis |
|---|
| Team Transparency | 50/100 | Key figures (Aubrey de Grey, Paul Kohlhaas) are named, but one source states the broader Bio team retains a degree of anonymity, leaving overall traceability mixed. |
| Fraud & Scam Risk | 60/100 | No hack, fraud, or rug-pull indicators tied specifically to Aubrai were found, but the sources contain no dedicated trust/security audit trail to confirm a clean record. |
| Use Case Legitimacy | 80/100 | Aubrai has a clearly documented real-world use case: an AI agent generating and funding longevity research hypotheses tied to a named scientist's lab. |
| Ethical Practices | 90/100 | The protocol's own design is aimed at funding scientific longevity research, which is not a prohibited sector. |
Summary: Aubrai links to named credentialed contributors (Dr. Aubrey de Grey, Paul Kohlhaas) though the broader development team retains partial anonymity, and no fraud or regulatory action was found tied to the project itself.
2. Project Operations (9 criteria)
| Criterion | Score | Analysis |
|---|
| Core Protocol Business | 85/100 | The base protocol operates in decentralized science/research funding, a sector with no inherent Shariah prohibition. |
| Transaction Fees | 65/100 | A 1% secondary-market fee splits 70% to the project treasury and 30% to the protocol, functioning as a disclosed service fee rather than an interest mechanism. |
| Treasury Assets | 55/100 | Treasury sits in a DAO-controlled multi-sig funded by sale proceeds and LP allocations, but no explicit statement confirms it avoids interest-bearing instruments. |
| Revenue Model | 75/100 | Revenue is generated from trading/market-making fees directed to research funding, not from interest-based lending. |
| Transparency | 70/100 | Detailed public documentation of tokenomics, legal classification, and an open-sourced BioAgent framework exist. |
| Governance | 50/100 | DAO governance rights are documented, but heavy pre-allocations to VitaDAO/Bio/initial funders and multi-sig treasury control suggest meaningful centralization. |
| Launch Fairness | 35/100 | The Ignition Sale was restricted to BIO/BioXP holders and heavily oversubscribed, with the majority of supply reserved for insiders/partners rather than the open public. |
| Token Distribution | 35/100 | Roughly 59% of total supply went to VitaDAO, initial funders, LEVF and Bio versus only 20% in the public sale, indicating concentrated distribution. |
| Speculation/Utility Ratio | 40/100 | Reports of a ~150x price rise and fee income framed as "speculation" revenue show trading activity currently dominates over steady utility usage. |
Summary: The protocol funds longevity research via an AI agent, uses a disclosed fee-split model and DAO-governed treasury, but launched through a restricted, insider-weighted Ignition Sale rather than a broadly open distribution.
3. Financial Health (4 criteria)
| Criterion | Score | Analysis |
|---|
| Protocol Revenue | 78/100 | Documented revenue derives from trading/market-making fees rather than interest-based sources. |
| Financial Status | 45/100 | Reported FDV swings (from ~$269K to ~$40M) point to high volatility and limited financial stability data. |
| Interest Assessment | 75/100 | No lending or borrowing function is described for the AUBRAI protocol itself; a separate BIO-Aave lending proposal is ecosystem-level and not part of AUBRAI's own design. |
| Audit Quality | 12/100 | No audit report specific to Aubrai or its smart contracts appears anywhere in the sources, despite audit information being available for unrelated projects. |
Summary: Aubrai generates fee-based revenue from trading activity to fund research, shows significant price volatility, and lacks any identifiable smart-contract security audit in the sources reviewed.
4. Token Economics (5 criteria)
| Criterion | Score | Analysis |
|---|
| Token Purpose | 65/100 | Legal documentation explicitly labels AUBRAI a utility token tied to DAO governance rather than a pure meme token. |
| Governance Rights | 75/100 | Holders can propose and vote on DAO governance proposals per the project's own legal documentation. |
| Rewards Distribution | 72/100 | Funding/reward flow is variable, tied to trading and market-making fee income rather than a fixed payout. |
| Speculation Controls | 35/100 | Partial multi-year vesting exists for some allocations, but large immediately-liquid tranches and a reported 150x price surge show controls are insufficient against speculation. |
| Asset Backing | 50/100 | Value is tied to ongoing research funding, hypotheses, and IP-NFT activity rather than hard collateral, with no explicit backing mechanism described. |
Summary: AUBRAI is formally a governance utility token with variable, activity-based funding flows and partial vesting controls, though heavy speculative trading undercuts its utility-first design.
5. Staking Mechanism (5 criteria)
| Criterion | Score | Analysis |
|---|
| Mechanism Type | 45/100 | Staking of AUBRAI to earn BioXP is confirmed live, but custodial status, lock-ups, and slashing terms are not detailed in the sources. |
| Islamic Contract Classification | 35/100 | The staking-for-BioXP mechanism resembles a participation/access reward rather than a clean profit-sharing contract, and its Islamic classification is not addressed in the sources. |
| Rewards Structure | 55/100 | Rewards are BioXP points tied to staking/participation and expire after 14 days, suggesting variability, but the underlying value driver is not fully explained. |
| Documentation | 30/100 | Only brief descriptions of staking and BioXP mechanics were found; comprehensive terms and risk disclosures are not evidenced. |
| Shariah Alignment | 35/100 | The unclear contractual nature of the staking/BioXP reward system leaves an unresolved question about its Shariah classification. |
Summary: A staking mechanism exists (staking AUBRAI or BIO to earn BioXP points for future sale access), but its custodial structure, lock-up terms, and Islamic contract classification are not clearly documented in available sources.
Overall Assessment: Aubrai presents a genuine, well-documented research-funding use case with real governance rights, but its concentrated insider allocation, unaudited status, high price speculation, and under-documented staking terms leave several Shariah-relevant questions unresolved.
Scoring note: Meme cap applied: overall limited to 45 (C13=40, low utility -> Haram); maysir governs and is independently disqualifying.
Written by ThanvirFounder, Ex Director S&P Global Energy
Reviewed by Imam Omar SiddiqiShariah Scholar